QTC intervals can be assessed with the AliveCor heart monitor in patients on dofetilide for atrial fibrillation.

We assessed the feasibility of AliveCor tracings for QTC assessment in patients receiving dofetilide. Five patients with persistent AF underwent the two-handed measurement (mimicks Lead I). On the ECG, Lead I or II was used. There was no significant difference between the AliveCor-QTC and ECG-QTC (all ±20 msec). The AliveCor device can be used to monitor the QTC in these patients.